Background

Broadening the delivery of messenger RNA (mRNA) to organs and cells beyond the liver requires examining the structure and properties of carrier materials. A review published in the international journal Biomaterials Science summarizes structural commonalities among lipids and lipid-like materials and their relationships to mRNA delivery performance and targeting of specific organs and cells. Rather than reporting experimental results that directly validate a new material’s performance, the paper reviews the development and application prospects of related materials.

The authors explain that although applications of mRNA therapies have advanced since the COVID-19 pandemic, the accumulation of traditional lipid carriers in the liver has constrained efforts to broaden their use. This has prompted continued development of materials intended to target organs or cells outside the liver. The provided abstract does not report accumulation patterns by administration route or delivery fractions by organ, so the extent of liver accumulation cannot be compared quantitatively.

Key findings

The review focuses on the relationship between carrier structure and properties and mRNA expression efficiency. According to the abstract, expression efficiency is closely associated with carrier structure and properties. Building on this understanding of structure–function relationships, lipids and lipid-like molecules have been developed to target organs or cells beyond the liver. The materials reviewed include lipid analogues and lipid-like polymers.

The authors summarize structural features shared by materials associated with strong delivery performance and targeting of specific organs and cells. The discussion centers on the materials that make up the carrier. It should not be interpreted as establishing new principles for the genomic design of mRNA itself. The review’s central approach is to examine the links between delivery-material structure and performance.

However, the available abstract does not describe specific chemical structures or mechanisms of action. The number of materials reviewed, the experimental subjects and comparison conditions in individual studies, and the degree of improvement in delivery efficiency could not be confirmed either. Therefore, this source alone cannot establish which materials were delivered to which organs and with what degree of selectivity, or by how much their expression efficiency exceeded that of existing carriers.

Implications and outlook

For materials research aimed at broadening the target range of mRNA therapies, this review presents an approach that considers carrier structure and properties alongside performance. It covers lipid analogues and polymers as well as lipids, and may serve as a starting point for exploring literature on materials relevant to delivery beyond the liver.

The potential applications of materials should be distinguished from evidence of therapeutic benefit. The abstract discusses biomedical applications and future prospects for these materials, but provides no data for assessing treatment effects in a particular disease or whether patient-tailored delivery has been achieved. Reduced adverse effects and clinical efficacy are also not findings established by this abstract.

Using the review to inform further development requires examining its full text and the individual studies it cites. Assessing the applicability of candidate materials requires considering target organs and cells, experimental conditions, comparators, expression results, and safety data together. The evidence available here is limited to outlining this direction for further assessment.

Source: Europe PMC bibliographic record and abstract.